Drug name: Grn163l


Related CSCTT Targets

Telomerase [ref.1]O14746

Grn163L, Imetelstat sodium

Cas.no PubChem ID
1007380-31-5 72941968
Known Target
Telomerase-binding protein EST1AQ86US8
N-terminal kinase-like proteinQ96KG9
Prostaglandin E synthase 3Q15185
Telomerase reverse transcriptaseO14746
Introduction
GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the its potential utility in the treatment of patients with hematologic and solid tumor malignancies. GRN163L has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types. It targets the template region, or active site, of telomerase. GRN163L does not exhibit antisense activity (binding to messenger RNA), but rather directly bind to the RNA component of telomerase at the active site of the enzyme, thereby acting like a conventional pharmaceutical drug. Inhibiting telomerase activity should result in telomere shortening and therefore cause aging and death of cancer cells.

Grn163L, Imetelstat sodium-Structure

...

Reference

  • [1] Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. Brennan, S. K., et al. (2010).PLoS One.5(9). pii: e12487.
    20824134. [ 20824134 ]

Back to top